• 분석과학
• /
• 제20권2호
• /
• pp.138-146
• /
• 2007

본 연구에서는 비글견 혈장 중의 파록세틴을 액체상추출법(LLE)으로 전처리하고 액체크로마토그래피-탠덤질량분석기(LC-MS/MS)로 신속하게 분석하는 방법을 개발하였다. 파록세틴과 내부표준물질로 사용한 플루오세틴을 TBME(tert-butyl methyl ether)로 추출하고 상층액을 취하여 건조시킨 후, 이동상 $100{\mu}L$로 재분산하여 LC-MS/MS에 주입하였다. HPLC 분석조건으로 Capcell Pak UG120($2.0{\times}150mm$, $5{\mu}m$) 컬럼을 사용하였으며, 이동상은 50% 아세토니트릴(pH 3, formic acid로 조정) 용액을 사용하였고, 유량은 0.2 mL/min으로 하였다. MS/MS의 SRM(selective reaction monitoring) 방법으로 파록세틴과 플루오세틴의 선구 이온, 생성 이온을 각각 m/z $330{\rightarrow}192$, m/z $310{\rightarrow}148$로 분석한 결과 0.02~5 ng/mL의 농도범위에서 상관계수($R^2$) 0.9993으로 좋은 직선성을 나타내었다. 또한 정량한계는 0.02 ng/mL이며, 정밀성은 일내 및 일간 변동계수가 7.67% 이하이고, 정확도는 92.96~102.99%로 비글견 혈장 중의 파록세틴의 약물동력학 연구에 이용될 수 있는 충분한 감도와 특이성, 직선성, 정밀성 및 정확성을 갖고 있음을 확인하였다.

• 대한불안의학회지
• /
• 제3권2호
• /
• pp.110-115
• /
• 2007

Objective : The authors examined the treatment response and remission rates in patients with panic disorder after short-term pharmacotherapy in an effort to determine the factors that can be used to predict remission in Korean patients with panic disorder. Methods : Sixty-one patients with panic disorder were recruited for participation in this study. The psychological symptoms of the patients were measured using the HAMA, HAMD, STAIS, STAIT, ASI and API at baseline and after 3 months of pharmacotherapy. Results : Patients with panic disorder showed significantly lower scores on all psychological measures after 3 months of pharmacotherapy with paroxetine. The remission rate was 44.3%, and the response rate was 54.1%. The remitters showed significantly lower HAMD, HAMA, STAIS, STAIT, and ASI scores than the non-remitters. Linear regression analysis revealed that the baseline HAMA, HAMD, and ASI scores could be used to predict the remission rate after controlling for age, sex and agoraphobia. Conclusion : Compared with previous reports, our study showed a similar remission rate in Korean patients with panic disorder. Lower baseline levels of anxiety, depression, and anxiety sensitivity were found to be predictors of treatment remission in panic disorder.

• 생물정신의학
• /
• 제3권2호
• /
• pp.251-257
• /
• 1996

Selective serotonin reuptake inhibitors(SSRIs), as haloperidol, ore metabolized in the cytochrome P450IID6. They can cause inhibition of metabolism of antipsychotics to elevate the serum level of antipsychotics and exacerbate the extrapyramidal symptoms when co-administered with antipsychotics. Among these SSRIs, there ore a few studies about paroxetine compared to fluoxetine or sertraline. In this study, we have intended to know the drug interaction of paroxetine and haloperidol when co-administered two drugs for the chronic schizophrenics by assessing the changes of positive, negative symptoms and extrapyramidal symptoms. for this purpose, we selected 29 subjects, the chronic schizophrenics with no physical problems. They were under maintenance therapy of haloperidol. They ore randomly assigned to placebo group(n=12) and drug group(n=17) by using double blind method. And then, placebo or paroxetine 20mg were administered to the subjects of each groups during 8 week period. We have assessed their psychopathology and extrapyramidal symptoms using Positive and Negative Syndrome Scale(PANSS), Hamilton Rating Scale lor Depression(HRSD), Simpson-Angus Scale at 0, 2, 4, 6, 8 weeks and serum haloperidol, reduced haloperidol levels at 0, 4, 8 weeks during the period. The results ore analysed by using repeated measure MANOVA. 27 subjects have completed the study during 8 weeks. among the subjects, 1) PANSS, HRSD ; no significant difference between groups. 2) Simpson-Angus Scale ; no significant change according to the time and no significant difference between the groups(no group and time effect). 3) Haloperidol and reduced haloperidol level ; no significant change. When co-administered paroxetine and haloperidol, there ore no significant changes of the psychopothology and no significant changes of the extrapyramidal symptoms. In this result, paroxetine seems to be not to affect the metabolism of haloperidol.

• 대한불안의학회지
• /
• 제2권2호
• /
• pp.101-107
• /
• 2006

Object : Since autonomic nerve system dysfunction was known as the mechanism of panic disorder, many researchers used heart rate variability (HRV) as means of measuring autonomic nerve function of patients with panic disorder. We aimed to examine the effect of paroxetine medication for 3 months on symptom improvement and change of heart rate variability of the patients with panic disorder. Methods : The subjects were patients with panic disorder who visited the psychiatric outpatient clinic of Samsung Medical Center in Seoul. We included panic disorder patients who were aged from 20 to 50 and in normal BMI range (from 18 to 30) to minimize the effect of age and weight on HRV data. We excluded the patients with EKG abnormalities, hypertension or other major psychiatric disorders. They took 20-40 mg paroxetine medication a day for 3 months. Alprazolam was used only during the first month to control the acute panic symptoms and was tapered off after that. We measured the acute panic inventory (API), Hamilton rating scale for anxiety and depression (HAM-A & HAM-D), Spielberger state-trait anxiety inventory (STAIS, STAIT), and Beck depression inventory (BDI) in order to assess clinical improvement of the patients. And we measured time and frequency domain HRV in the resting, standing and cognitive stress states to assess the change of HRV. All measurements were done before and after paroxetine treatment. Result : After paroxetine medication, patients showed significant improvement in all psychiatric scales. In time domain of HRV, standard deviations of all R-R intervals (SDNN) were significantly increased in all states. In frequency domain of HRV, the ratio of high frequency to total power (HF/TP) in the standing state was significantly increased. Conclusion : After 3 months paroxetine medication, panic disorder patients showed significant clinical improvement and change in HRV data such as SDNN in all states and HF/TP ratio in the standing state. This result suggests that paroxetine medication is effective for the improvement of autonomic nerve system dysfunction in panic disorder patients.

• Journal of Pharmaceutical Investigation
• /
• 제34권6호
• /
• pp.499-504
• /
• 2004

Paroxetine, a potent and selective serotonine reuptake inhibitor, has been used for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. The bioequivalence of two paroxetine preparations was evaluated according to the guidelines of Korea Food & Drug Administration (KFDA). The test product was Samchully Paroxetine $tablet^{\circledR}$ made by Samchully Pharm. Co. and the reference product was Seroxat $tablet^{\circledR}$ made by GlaxoSmithKline. Twenty healthy male subjects, $22.4{\pm}2.6$ years old and $63.8{\pm}4.2\;kg$, were divided into two groups and a randomized $2{\times}2$ cross-over study was employed. After one tablet containing 20 mg paroxetine was orally administered, blood was taken at predetermined time intervals and the concentration of paroxetine in plasma was determined using a validated HPLC method with fluorescence detector. Two pharmacokinetic parameters, $AUC_t$ and $C_{max}$, were calculated and analyzed statistically for the evaluation of bioequivalence of two products. Analysis of variance was carried out using logarithmically transformed parameter values. The 90% confidence intervals of $AUC_t$ and $C_{max}$ were log 0.84-log 1.16 and log 0.85-log 1.14, respectively. These values were within the acceptable bioequivalence intervals of log 0.8 to log 1.25. Thus, the criteria of the KFDA guidelines for the bioequivalence was satisfied, indicating that Samchully Paroxetine tablet is bioequivalent to Seroxat tablet.